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Identification of inherited cancer-predisposing genes offers opportunities for cancer prevention. Inherited susceptibility genes have been identified,
primarily through studies of unusual cancer cases and families but also through general population studies. Examples include the RB1 gene for
retinoblastoma; the INT1 gene for Wilms' tumor; germline p53 mutations in families with the Li-Fraumeni syndrome; the NF1 and NF2 genes for
neuroblastomatosis, types 1 and 2; the VHL gene for renal cancer and other tumors associated with Von Hippel-Lindau disease; the APC gene for
adenomatous polyposis coli; the BRCA1 gene for hereditary breast and ovarian cancer; and the mismatch repair genes for colon and other common
cancers. For some cancers, identification of gene carriers might be beneficial for targeting screening and chemopreventive interventions. On the
other hand, predisposition testing for cancer has the potential for harm from loss of insurability and employability, psychological distress, social
stigmatization and other adverse effects. Research is needed to identify predisposition testing procedures that maximize benefits while minimizing
harm to subjects. Chemoprevention trials in genetically susceptible populations offer the prospect of finding effective methods of reducing future
cancer risk. - Environ Health Perspect 103(Suppl 8):297-300 (1995)
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Introduction
Speakers at this meeting have summarized
current knowledge of cancer etiology and
considered opportunities for prevention.
Epidemiological studies ofhuman popula-
tions have demonstrated the carcinogenic
effects ofionizing and ultraviolet radiation,
tobacco, alcoholic beverages, viral and bacte-
rial agents, and chemical compounds (1,2).
In the 1994Annual Report on Carcinogens
(3), nearly two dozen substances, occupa-
tional exposures, and medical treatments
were classified as carcinogenic in humans.
Many more substances were said to be "rea-
sonably anticipated to be carcinogens," but
uncertainties remain. Presently, known car-
cinogens account for perhaps half the inci-
dent cancers in the United States. For
many common forms of cancer, such as
cancers of the breast, prostate, and gas-
trointestinal tract, lifestyle factors have
been implicated, although specific causes
have been difficult to pinpoint.
A constant challenge to cancer epidemi-
ologists is the relatively small excess risk
associated with exposures to many suspected
carcinogens (4). To overcome the problem,
This paper was presented at the President's
Cancer Panel Conference on Avoidable Causes of
Cancer held 7-8 April 1994 in Bethesda, Maryland.
Manuscript received 9 March 1995; manuscript
accepted 24 March 1995.
Address correspondence to Dr. Frederick P. Li,
Dana-Farber Cancer Institute, 44 Binney Street,
Boston, MA 02115. Telephone: (617) 632-3158. Fax:
(617) 632-3161. E-mail: frederick_li@dfci.harvard.edu
researchers are utilizing laboratory tools
to refine dose-response relationships and
to reinforce the biological plausibility of
hypotheses (5). Molecular biomarkers also
can be applied to classify patients and
strengthen associations in study subgroups
(6). In this emerging era ofmolecular epi-
demiology, substantial progress has been
made in the identification ofinherited sin-
gle-gene traits that markedly increase cancer
risk (7). In the future, the knowledge ofthe
more complex genetic systems involved in
the activation and detoxification ofcarcino-
gens should further enhance the power of
cancer epidemiology, as described in
Rothman's paper (8). This overview will
explore opportunities for cancer prevention
based on recent discoveries of inherited
cancer-predisposing genes.
CancerFanilies andCancer
Susceptibility Genes
Historically, the effects ofinherited cancer
susceptibility genes were discerned through
studies of cancer occurrence in families.
More recent advances in cytogenetics pro-
vided the first glimpses ofinherited genetic
changes that confer susceptibility to cancer.
In 1986, the first inherited cancer suscepti-
bility gene, the RB1 gene for retinoblastoma,
was cloned (9). Since then, a dozen such
genes have been identified, mostly through
studies ofunusual cases and families.
Epidemiological studies have consis-
tently shown that a family history ofcancer
is a risk factor forvirtually all forms ofneo-
plasia in humans (10). The relative risk is
typically 1.5- to 3-fold for the forms of
cancer that have occurred in close relatives.
In some instances, the elevated risk extends
to multiple organ sites, as in the multiple
endocrine neoplasia syndromes (11).
Familial aggregation of cancers is usually
attributed to inherited susceptibility,
although shared exposures to environmen-
tal hazard among close relatives often can-
not be excluded. For the common forms of
cancers, chance aggregation among blood
relatives is a third explanation. Historically,
inherited susceptibility factors seldom were
the focus of epidemiological research, in
part because laboratory tools for genetic
analyses were rudimentary. Inherited pre-
disposition was also viewed as immutable,
whereas environmental carcinogens should
be avoidable. The attributable risk ofindi-
vidual genes seems trivial compared with
the effects oftobacco and sunlight exposure.
However, the relative risk is exceptionally
high among carriers ofmany inherited can-
cer susceptibility genes. The lifetime risk of
specific cancers is 80 to 90% among carri-
ers of certain susceptibility genes. These
persons often are prone to early onset
disease and multiple primary cancers.
Cancer in certain families appears to be
transmitted as an autosomal dominant
trait with high penetrance. Clinical obser-
vations at the bedside have helped to iden-
tify inherited susceptibility genes, and
affected families. Epidemiological studies
of these kindreds have quantitated their
excess risk. Laboratory studies have helped
clarify the biological basis ofsusceptibility,
Environmental Health Perspectives 297F.P. Li
including identification ofinherited cancer- Major discoveries in the last year
predisposing genes. Genes found to date include identification of the BRCA1 gene
include tumor suppressor genes, an onco- for hereditary breast and ovarian cancer and
gene (RET), and more recently, mismatch the mismatch repair genes (MSH2, MLH1,
repair genes (11,12). In these studies, and PMSI and PMS2) for colon and other
clinicians and epidemiologists provided common cancers (16-18). Discovery of
the tissue specimens essential to the mole- these genes has vastly increased the num-
cular discoveries by laboratory scientists. bers of cancer susceptibility gene carriers
Identification of inherited susceptibility who can be identified. In contrast to the
genes has, in turn created new clinical rarity ofcarriers of RBI, WTI, p53, APC,
opportunities to reduce cancer morbidity and RET, approximately 5% ofbreast or
and mortality. colon cancer patients might carry an inher-
Retinoblastoma is a prototypic heredi- ited susceptibility gene. Carriers ofsuscep-
tary cancer in humans (13). Mutations in tibility genes may account for more than
the retinoblastoma gene, even single- 10,000 cases ofbreast cancer and 10,000
nucleotide alterations, can confer a 90% cases ofcolon cancer diagnosed annually in
likelihood of development of cance-r" the United States. Up to 1 to 2 million
(9). Based on studies of retinoblastoma, Americans are estimated to carry a breast
Knudson developed a 2-mutation model or colon cancer susceptibility gene. Because
that, provided the conceptual framework survival from these cancers depends largely
for studying rare family aggregates of can- on disease stage, identification ofcarriers
cer to gain new understanding ofhuman for targeted interventions might be bene-
carcinogenesis (14). The model postulates ficial. However, seeking gene carriers in
that at least two mutations are required to cancer-free populations (genetic predisposi-
transform a normal cell into a cancer cell. tion testing or predictive testing) is new
At the molecular level, the same mutant (19). Benefits ofpredisposition testing are
genes are involved in both familial and determined largely by the availability of
sporadic (nonfamilial) forms of a cancer. prevention and early detection measures.
Patients with hereditary retinoblastoma On the other hand, predisposition testing
have inherited a germinal mutation and for cancer or other hereditary disease runs
subsequently acquired another in the sec- the risk ofharm from loss of insurability
ond RBI allele, whereas those with spo- and employability, psychological distress,
radic cancers had to acquire both RBI social stigmatization, and other adverse
mutations within one retinal cell. Despite affects. Research is needed to identify pre-
the rarity of retinoblastoma as a clinical disposition testing procedures that maxi-
diagnosis, recent studies have shown that mize benefits while minimizing harm to
acquired mutations in RBI can occur in subjects (20). Investigators, clinicians, gov-
most forms of cancer (15). Thus, studies ernmental agencies, and institutional
of a rare hereditary cancer led to the review boards are working to set guidelines
identification of a gene that is commonly to protect subjects who volunteer for test-
mutated during neoplastic transformation. ing (21). The social and ethical issues of
Knowledge ofthe structure and functions offering commercial testing to the general
of RBI might yield novel approaches to population are drawing headlines in both
therapy ofcancer in the future. the layand professional press.
Most known tumor suppressor genes Genetic research on human cancers is
have been discovered through studies of not new. Until inherited cancer susceptibil-
families with hereditary cancers: the WTi ity genes were cloned, however, genetic
gene for Wilms' tumor; germline p53 studies were limited to analyses ofsomatic
mutations in families with diverse child- mutations acquired during neoplastic
hood cancers, and early onset breast cancer transformation. The results had no rele-
(Li-Fraumeni syndrome); the NFl and vance to future cancer risks among relatives
NF2 genes for neurofibromatosis, types 1 ofthe patient. In marked contrast, cancer
and 2; the VHL gene for renal cancer and predisposition testing is conducted in can-
other tumors associated with von Hippel- cer-free individuals with the goal ofdisclos-
Lindau disease; and the APC gene for ing results that might sharply elevate
adenomatous polyposis coli (12). Mapping estimates offuture risk.
and cloning of these genes have been The potential for adverse effects ofdis-
facilitated by finding large affected families closure of inherited cancer susceptibility
and rare cases with constitutional chromo- requires that adequate safeguards be pro-
some markers, particularly translocations vided to test subjects (22,23). There must
and deletions. be freedom from coercion to be tested.
Informed consent is imperative, with
provisions for freedom to withdraw or
postpone disclosure. Before testing begins,
discussions are necessary regarding disclo-
sure of results to persons other than the
subject, including physicians, relatives, and
third parties. Providers of predisposition
testing should assess the mental and
emotional competence of test subjects.
Counseling and education should include
interpretation and limitations oftest results.
The investigators should be prepared to
manage complications of testing and to
follow up to assess long-term outcomes.
After new inherited susceptibility genes
such as BRCA1 and the colon cancer genes
are cloned, population surveys often are
conducted to assess population frequency
of inherited mutations. A dilemma is
whether to disclose individual or aggregate
results from these surveys to the partici-
pants. Surveys for mutations in large num-
bers ofspecimens in research laboratories
may not be as accurate as those conducted
by clinical laboratories where government
agencies monitor quality control. Consid-
ering the profound adverse effects of
reporting erroneous results, survey findings
probably should be considered preliminary
and not disclosed to individuals without
confirmation. In these survey studies, most
subjects do not show inherited mutations,
but the clinical significance of a negative
finding is problematical. Multiple inherited
susceptibility genes, some still unknown,
can predispose a person to breast, colon,
and other cancers. A negative test may sim-
ply mean that the mutation is in another
susceptibility gene. Thus, the absence of a
germline mutation is meaningless unless a
germline mutation was previously identified
in an affected relative.
A common misconception is that a
positive genetic test predicts that cancer
will develop, whereas a negative test is asso-
ciated with the baseline population fre-
quency for that cancer (23). This view
disregards data on risk conveyed by the
family and personal medical history.
Cancer predisposition testing modifies
clinical risk estimates but does not predict
with certainty when, where (organ site),
and ifcancer will develop. To convey these
concepts, counseling about cancer risk
should begin even before specimens are
collected for laboratory testing. Individuals
should be counseled on the basis offamily
history of cancer, personal history of
antecedent diseases, and known risk factors
such as hormonal and reproductive factors
for breast cancer. Risk estimates associated
Environmental Health Perspectives 298INHERITED CANCERSUSCEPTIBILITY
with family history can be refined further
on the basis ofnumber ofaffected relatives,
ages at diagnosis, relationship to the test
subject, and cases ofmultiple primary neo-
plasms. In this context, subsequent DNA
test results further refine risk estimates.
Identification ofan inherited suscepti-
bility gene per se provides no benefit to the
subject. Benefit from cancer predisposition
testing accrues when primary prevention,
targeted screening, and more effective
treatments lead to reduced morbidity and
mortality (24). Finding carriers of inheri-
ted susceptibility genes creates an obliga-
tion to develop strategies for the care of
these cancer-prone individuals. Increased
medical surveillance might detect early
cancers in at-risk organs and tissues. For
example, identification ofan inherited RBJ
mutation in an at-risk infant can lead to
surveillance and curative treatments with
minimal loss of eyesight. Benefits of tar-
geted screening might also accrue to carri-
ers ofcolon and breast cancer susceptibility
genes (25). Targeted colonoscopies can
lead to excision of pre-cancerous polyps,
but the procedure is neither inexpensive nor
free ofmorbidity. An alternative is primary
prevention through reducing exposures to
carcinogens among those with inherited
susceptibility to cancer. Avoidance ofsun-
light exposure in patients with xeroderma
pigmentosum or hereditary melanoma can
reduce the risk ofskin neoplasms. Dietary
modification might reduce the risk ofcolon
and other cancers in gene carriers, but sus-
tained change in dietary practices is diffi-
cult to achieve. There are a few indications
at present to perform prophylactic surgery
to remove the target organs in genetically
susceptible individuals. Prophylactic total
colectomy is standard treatment for patients
with adenomatous polyposis coli due to
the APCgene. However, morbidity of the
procedure is high, and deaths from dis-
moid tumors arising at the surgical site are
frequent. A few patients in breast-ovarian
cancer families have undergone prophylac-
tic mastectomy, oophorectomy, or both.
Unfortunately, abdominal carcinomatosis
have developed subsequent to prophylactic
oophorectomy in rare cases, and the
extent of risk reduction after prophylactic
mastectomy is not known
A new and exciting area of research is
chemoprevention (26). The goal ofchemo-
prevention is to prevent or delay cancer
occurrence through the use of chemical
agents. Chemopreventive agents under
study include natural and synthetic products
including vitamin micronutrients, natural
compounds, and pharmaceutical agents. A
growing number ofclinical chemopreven-
tion trials are in progress, and early results
from several studies have been encouraging.
Target populations in these studies include
cancer patients at high risk ofsecond can-
cers, those with precancerous lesions, and
carriers ofcancer susceptibility genes. The
latter are an attractive group for chemopre-
vention trials, in part because their risk of
future cancer development is exceptionally
high. In these groups, chemopreventive
agents with some toxicity might be accept-
able. Chemoprevention trials require large
numbers ofsubjects. When cancer preven-
tion is the end point, studies should be
extended over many years; their cost is
high. Intermediate biomarkers of efficacy
could give early indications of benefit.
Unfortunately, validated biomarkers have
been difficult to identify and their predic-
tive power is difficult to measure. Problems
notwithstanding, chemoprevention trials in
genetically susceptible populations offer
the prospect of finding effective methods
ofreducing future cancer risk.
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